Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

Akt/p70S6K inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (18) 5-HT Receptor (1) Amyloid-β (1) Apoptosis (8) ATM/ATR (1) Autophagy (3) Bcl-2 Family (1) Cholinesterase (ChE) (1) COX (1) EGFR (3) Epigenetic Reader Domain (1) ERK (1) FAK (1) Ferroptosis (1) FOXO (1) Fungal (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (2) HSP (1) HSV (1) Insulin Receptor (1) mTOR (4) Necroptosis (1) NF-κB (6) Notch (1) p38 MAPK (1) Parasite (1) PDK-1 (1) PI3K (4) PKA (3) PTEN (1) Reactive Oxygen Species (ROS) (2) Reference Standards (5) Ribosomal S6 Kinase (RSK) (7) ROCK (1) TGF-beta/Smad (3) VEGFR (2) γ-secretase (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Akt (18)

5-HT Receptor (1)

Amyloid-β (1)

Apoptosis (8)

ATM/ATR (1)

Autophagy (3)

Bcl-2 Family (1)

Cholinesterase (ChE) (1)

COX (1)

EGFR (3)

Epigenetic Reader Domain (1)

ERK (1)

FAK (1)

Ferroptosis (1)

FOXO (1)

Fungal (1)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (2)

HSP (1)

HSV (1)

Insulin Receptor (1)

mTOR (4)

Necroptosis (1)

NF-κB (6)

Notch (1)

p38 MAPK (1)

Parasite (1)

PDK-1 (1)

PI3K (4)

PKA (3)

PTEN (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (5)

Ribosomal S6 Kinase (RSK) (7)

ROCK (1)

TGF-beta/Smad (3)

VEGFR (2)

γ-secretase (1)

By Research Areas:

Cancer (25)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Targets Recommended: Akt

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13595

Chrysophanol 5+ Cited Publications Chrysophanic acid	EGFR	Cancer
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of *AKT* and *mTOR/p70S6K*.

HY-16071

AT13148 2 Publications Verification	Akt PKA ROCK Ribosomal S6 Kinase (RSK)	Cancer
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

HY-N0847

Micheliolide Maximum Cited Publications 8 Publications Verification	NF-κB PI3K Akt TGF-beta/Smad	Inflammation/Immunology Cancer
Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .

HY-13260

CCT128930 5+ Cited Publications	Akt Autophagy Apoptosis	Cancer
CCT128930 is a ATP-competitive and selective inhibitor of *AKT* (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

HY-100501

M2698 1 Publications Verification MSC2363318A	Ribosomal S6 Kinase (RSK) Akt	Cancer
M2698 (MSC2363318A) is an orally active, ATP competitive, selective *p70S6K* and *Akt* dual-inhibitor with IC₅₀s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .

HY-N10303

Withangulatin A 1 Publications Verification	COX Parasite Reactive Oxygen Species (ROS) Apoptosis p38 MAPK NF-κB Akt mTOR TGF-beta/Smad	Inflammation/Immunology Cancer
Withangulatin A is the inhibitor for COX-2. Withangulatin A inhibits MAPK, NF-κB, *Akt/mTOR/p70S6K* pathway, exhibits antitumor, anti-inflammatory and trypanocidal activities .

HY-12059

AT7867 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and *p70S6K/PKA* with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Infection Inflammation/Immunology Cancer
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including *Akt/mTOR/p70S6K, Erk1/2* and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .

HY-N0597

Panaxatriol 3 Publications Verification	Akt Insulin Receptor Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease Cancer
Panaxatriol is an orally active dammarane-type tetracyclic triterpene sapogenin. Panaxatriol enhances the phosphorylation levels of *Akt, insulin receptor and p70S6K* in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer ^[1][2][3].

HY-12059A

AT7867 dihydrochloride 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and *p70S6K/PKA* with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-13260A

CCT128930 hydrochloride 5+ Cited Publications	Akt Autophagy Apoptosis	Cancer
CCT128930 hydrochloride is a potent and selective inhibitor of *AKT* (IC₅₀=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .

HY-13787

XL-418	Akt Ribosomal S6 Kinase (RSK) GSK-3	Cancer
XL-418 is an orally active dual *Akt* and *p70S6K* inhibitor with IC₅₀s of 1 nM for Akt1 and 2 nM for p70S6K. XL-418 inhibits the phosphorylation of ribosomal protein S6 and GSK3β. XL-418 can be used for the study of prostate carcinoma and breast cancer .

HY-N11709

Theasaponin E1	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal	Infection Neurological Disease Metabolic Disease Cancer
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of *Akt, mTOR, p70S6K* and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-126257

AKT-IN-3	Akt Apoptosis	Cancer
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking *Akt* inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .

HY-13595R

Chrysophanol (Standard) Chrysophanic acid (Standard)	Reference Standards EGFR	Cancer
Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of *AKT* and *mTOR/p70S6K*.

HY-124348

DM-PIT-1 3,5-Dimethyl PIT-1	PI3K	Cancer
DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer .

HY-N1333

Rubioncolin C	NF-κB	Cancer
Rubioncolin C exerts anti-tumor activity by inducing apoptotic and autophagic Cell Death and inhibiting the NF-κB and *Akt/mTOR/P70S6K* Pathway in Human Cancer Cells .

HY-117885

PF-5177624	PDK-1	Cancer
PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting *PI3K/AKT/mTOR/p70S6K* signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-N0597R

Panaxatriol (Standard)	Reference Standards Others	Others
Panaxatriol (Standard) is the analytical standard of Panaxatriol. This product is intended for research and analytical applications. Panaxatriol is an orally active dammarane-type tetracyclic triterpene sapogenin. Panaxatriol enhances the phosphorylation levels of *Akt, insulin receptor and p70S6K* in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer .

HY-100501R

M2698 (Standard) MSC2363318A (Standard)	Ribosomal S6 Kinase (RSK) Reference Standards Akt	Cancer
M2698 (Standard) is the analytical standard of M2698 (HY-100501). This product is intended for research and analytical applications. M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .

HY-155721

22-(4′-py)-JA 22-4′-Pyridinecarbonyl jorunnamycin A	Akt mTOR	Cancer
22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .

HY-N0847R

Micheliolide (Standard)	Reference Standards NF-κB PI3K Akt TGF-beta/Smad	Inflammation/Immunology Cancer
Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .

HY-182914

NGI-189	EGFR Akt Bcl-2 Family Apoptosis	Cancer
NGI‑189 is a selective OST‑A inhibitor. NGI‑189 inhibits the STT3A catalytic subunit of the OST complex and reduces N‑glycosylation of target glycoproteins. NGI‑189 blocks oncogenic and bypass signaling, reduces phosphorylation of EGFR, *AKT, p70S6K* and S6RP, and induces cell cycle arrest and apoptosis. NGI‑189 markedly suppresses tumor growth and induces tumor regression in non‑small cell lung cancer (NSCLC) xenograft models. NGI‑189 can be used for the research of EGFR‑mutant non‑small cell lung cancer .

HY-103100R

SB-699551 (Standard)	Reference Standards 5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO	Neurological Disease Cancer
SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a K_i value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.

Cat. No.	Product Name	Category	Target	Chemical Structure